Modality
Peptide
MOA
GLP-1ag
Target
TNFα
Pathway
DDR
Prostate Ca
Development Pipeline
Preclinical
Jul 2018
→ Dec 2031
PreclinicalCurrent
NCT06103400
368 pts·Prostate Ca
2018-07→2031-12·Terminated
NCT08134344
1,544 pts·Prostate Ca
2023-11→2027-10·Recruiting
1,912 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-021.5y awayInterim· Prostate Ca
2031-12-095.7y awayInterim· Prostate Ca
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Termina…
Preclinical
Recruit…
Catalysts
Interim
2027-10-02 · 1.5y away
Prostate Ca
Interim
2031-12-09 · 5.7y away
Prostate Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06103400 | Preclinical | Prostate Ca | Terminated | 368 | EASI-75 |
| NCT08134344 | Preclinical | Prostate Ca | Recruiting | 1544 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| ILM-5680 | Illumina | Phase 2 | BET |